Nadolol and propranolol were compared in seventy-five hypertensive patients in a double-blind randomized study conducted at Ain-Shams Hospital. After an initial wash-out period of 5 weeks, including 3 weeks of placebo administration, forty-five patients were given nadolol once daily and thirty patients received propranolol four times per day for 12 weeks, followed by a tapering-off period of 2 weeks. Both beta-blocking agents were effective in controlling hypertension with final daily doses ranging from 80 to 320 mg. Of statistical significance, however, were the better responses of supine systolic blood pressure elicited by nadolol. The only adverse reactions that occurred in this series were slight weight gains in two patients treated with nadolol and moderate dizziness in one patient treated with propranolol. Nadolol was proved to be a safe antihypertensive drug, at least comparable to propranolol in efficacy, with the advantages of a once-daily dose and a lack of direct depressant action on the heart.
Epicillin was administered orally, using a twice daily dosage regimen, to a total of 266 patients suffering from mild to moderate respiratory or urinary tract infections. The dosage used was 500 mg twice daily in respiratory tract infections and 1000 mg twice daily in urinary tract infections. The incidence of adverse reactions was 10% in this study and with one exception all were mild to moderate in severity. Epicillin administered on a twice daily basis proved to be efficacious against the common sensitive pathogens responsible for infection of the respiratory and urinary tracts. An excellent response was reported in 49% of the patients, a good response obtained in 46% and a fair response was achieved in 4%. The advantages of a twice daily dosage regimen are pointed out.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.